Dilution of rocuronium to 0.5 mg/mL with 0.9% NaCl eliminates the pain during intravenous injection in awake patients.
In a randomized, double-blinded, controlled study, we evaluated the effect of diluting rocuronium 10 mg/mL to 1 or 0.5 mg/mL with 0.9% NaCl on the pain associated with IV administration of rocuronium with small doses given before succinylcholine or nondepolarizing agent administration. One hundred fifty patients undergoing surgical procedures that required general anesthesia were randomized into three groups. Group 1 received rocuronium 10 mg/mL. Groups 2 and 3 received 1 and 0.5 mg/mL of rocuronium, respectively. Patient demographics, pain scores, osmolality, and the pH of the solutions were recorded. Group 1 had the most intense and frequent pain response. Eighty percent of patients in this group reported pain on injection. In Group 2, the incidence and intensity of pain were significantly less when compared with those of Group 1. In this group, 38% of patients reported pain during injection. In Group 3, none of the patients experienced pain on injection. The pH values and osmolalities of study solutions were not significantly different among groups. In conclusion, in awake patients, dilution of rocuronium 10 mg/mL at small doses given before succinylcholine or nondepolarizing agent administration of 0.06 mg/kg to 0.5 mg/mL with 0.9% NaCl is a simple and cost-effective strategy for preventing pain during IV rocuronium injection.
Tuncali
Bahattin
B
Department of Anesthesiology and Reanimation, Dokuz Eylul University, İzmir, Turkey.
Karci
Ayse
A
Tuncali
Binnur Erdalkiran
BE
Mavioglu
Omur
O
Olguner
Cimen Gulben
CG
Ayhan
Selin
S
Elar
Zahide
Z
D000328:Adult; D000368:Aged; D000732:Androstanols / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D009994:Osmolar Concentration; D010146:Pain / Q000517:prevention & control*; D000077123:Rocuronium; D012965:Sodium Chloride / Q000008:administration & dosage*; D014851:Wakefulness
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D012965:Sodium Chloride; D000077123:Rocuronium